DOCSLIB.ORG

Standards of Medical Care in Diabetes—2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Standards of Medical Care in Diabetes—2017 THE JOURNAL OF CLINICAL AND APPLIED RESEARCH AND EDUCATION VOLUME 40 | SUPPLEMENT 1 WWW.DIABETES.ORG/DIABETESCARE JANUARY 2017 PLE M E P N U T S 1 AMERICAN DIABETES ASSOCIATION STANDARDS OF MEDICAL CARE IN DIABETES—2017 ISSN 0149-5992 American Diabetes Association Standards of Medical Care in Diabetesd2017 January 2017 Volume 40, Supplement 1 [T]he simple word Care may suffice to express [the journal’s] philosophical mission. The new journal is designed to promote better patient care by serving the expanded needs of all health professionals committed to the care of patients with diabetes. As such, the American Diabetes Association views Diabetes Care as a reaffirmation of Francis Weld Peabody’s contention that “the secret of the care of the patient is in caring for the patient.” —Norbert Freinkel, Diabetes Care, January-February 1978 EDITOR IN CHIEF William T. Cefalu, MD ASSOCIATE EDITORS EDITORIAL BOARD George Bakris, MD Nicola Abate, MD Maureen Monaghan, PhD, CDE Lawrence Blonde, MD, FACP Vanita R. Aroda, MD Kristen J. Nadeau, MD, MS Andrew J.M. Boulton, MD Geremia Bolli, MD Kwame Osei, MD David D’Alessio, MD John B. Buse, MD, PhD Kevin A. Peterson, MD, MPH, FRCS(Ed), Mary de Groot, PhD Robert J. Chilton, DO, FACC, FAHA FAAFP Eddie L. Greene, MD Kenneth Cusi, MD, FACP, FACE Jonathan Q. Purnell, MD Frank B. Hu, MD, MPH, PhD Paresh Dandona, MD, PhD Peter Reaven, MD Steven E. Kahn, MB, ChB J. Hans DeVries, MD, PhD Ravi Retnakaran, MD, MSc, FRCPC Derek LeRoith, MD, PhD Ele Ferrannini, MD Helena Wachslicht Rodbard, MD Robert G. Moses, MD Franco Folli, MD, PhD Elizabeth Seaquist, MD Stephen Rich, PhD Meredith A. Hawkins, MD, MS Guntram Schernthaner, MD Matthew C. Riddle, MD Richard Hellman, MD David J. Schneider, MD Julio Rosenstock, MD Norbett Hermanns, PhD, MSc Norbert Stefan, MD William V. Tamborlane, MD George S. Jeha, MD Jan S. Ulbrecht, MB, BS Katie Weinger, EdD, RN Irl B. Hirsch, MD, MACP Joseph Wolfsdorf, MD, BCh Judith Wylie-Rosett, EdD, RD Lee M. Kaplan, MD, PhD Tien Yin Wong, MBBS, FRCSE, FRANZCO, M. Sue Kirkman, MD MPH, PhD Ildiko Lingvay, MD, MPH, MSCS Bernard Zinman, CM, MD, FRCPC, FACP Harold David McIntyre, MD, FRACP AMERICAN DIABETES ASSOCIATION OFFICERS CHAIR OF THE BOARD David A. DeMarco, PhD PRESIDENT, MEDICINE & SCIENCE Alvin C. Powers, MD PRESIDENT, HEALTH CARE & EDUCATION Brenda Montgomery, RN, MSHS, CDE SECRETARY/TREASURER Umesh Verma CHIEF EXECUTIVE OFFICER Kevin L. Hagan The mission of the American Diabetes Association is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. Diabetes Care is a journal for the health care practitioner that is intended to increase knowledge, stimulate research, and promote better management of people with diabetes. To achieve these goals, the journal publishes original research on human studies in the following categories: Clinical Care/Education/Nutrition/ Psychosocial Research, Epidemiology/Health Services Research, Emerging Technologies and Therapeutics, Pathophysiology/Complications, and Cardiovascular and Metabolic Risk. The journal also publishes ADA statements, consensus reports, clinically relevant review articles, letters to the editor, and health/medical news or points of view. Topics covered are of interest to clinically oriented physicians, researchers, epidemiologists, psychologists, diabetes educators, and other health professionals. More information about the journal can be found online at care.diabetesjournals.org. Copyright © 2017 by the American Diabetes Association, Inc. All rights reserved. Printed in the USA. Requests for permission to reuse content should be sent to Copyright Clearance Center at www.copyright.com or 222 Rosewood Dr., Danvers, MA 01923; phone: (978) 750-8400; fax: (978) 646-8600. Requests for permission to translate should be sent to Permissions Editor, American Diabetes Association, at [email protected]. The American Diabetes Association reserves the right to reject any advertisement for any reason, which need not be disclosed to the party submitting the advertisement. Commercial reprint orders should be directed to Sheridan Content Services, (800) 635-7181, ext. 8065. Single issues of Diabetes Care can be ordered by calling toll-free (800) 232-3472, 8:30 A.M. to 5:00 P.M. EST, Monday through Friday. Outside the United States, call (703) 549-1500. Rates: $75 in the United States, $95 in Canada and Mexico, and $125 for all other countries. Diabetes Care is available online at care.diabetesjournals.org. Please call the numbers listed above, e-mail [email protected], or visit the online journal for more information about submitting manuscripts, publication charges, ordering reprints, PRINT ISSN 0149-5992 subscribing to the journal, becoming an ADA member, advertising, permission to reuse ’ ONLINE ISSN 1935-5548 content, and the journal s publication policies. PRINTED IN THE USA Periodicals postage paid at Alexandria, VA, and additional mailing offices. AMERICAN DIABETES ASSOCIATION PERSONNEL AND CONTACTS VICE PRESIDENT, PUBLISHER EDITORIAL CONTENT MANAGER ADVERTISING SALES Michael Eisenstein Nancy C. Baldino ASSOCIATE PUBLISHER, PHARMACEUTICAL/DEVICE DIGITAL ADVERTISING SCHOLARLY JOURNALS TECHNICAL EDITORS e-Healthcare Solutions Christian S. Kohler Oedipa Rice John Burke Theresa Cooper Chief Revenue Officer EDITORIAL OFFICE DIRECTOR [email protected] Lyn Reynolds ASSOCIATE DIRECTOR, BILLING & COLLECTIONS (609) 882-8887, ext. 149 PEER REVIEW MANAGER Laurie Ann Hall Shannon Potts PHARMACEUTICAL/DEVICE PRINT ADVERTISING DIRECTOR, MEMBERSHIP/SUBSCRIPTION The Jackson-Gaeta Group, Inc. EDITORIAL ASSISTANT SERVICES B. Joseph Jackson Joan Garrett Donald Crowl [email protected] DIRECTOR, SCHOLARLY JOURNALS Paul Nalbandian SENIOR ADVERTISING MANAGER Heather Norton Blackburn [email protected] Julie DeVoss Graff Tina Auletta CONTENT PRODUCTION MANAGER [email protected] [email protected] Kelly Newton (703) 299-5511 (973) 403-7677 January 2017 Volume 40, Supplement 1 Standards of Medical Care in Diabetes—2017 S1 Introduction S75 9. Cardiovascular Disease and Risk S3 Professional Practice Committee Management S4 Standards of Medical Care in Diabetes—2017: Hypertension/Blood Pressure Control Summary of Revisions Lipid Management S6 1. Promoting Health and Reducing Disparities in Antiplatelet Agents Populations Coronary Heart Disease Diabetes and Population Health S88 10. Microvascular Complications and Tailoring Treatment to Reduce Disparities Foot Care S11 2. Classification and Diagnosis of Diabetes Diabetic Kidney Disease Diabetic Retinopathy Classification Neuropathy Diagnostic Tests for Diabetes Foot Care Categories of Increased Risk for Diabetes (Prediabetes) Type 1 Diabetes S99 11. Older Adults Type 2 Diabetes Gestational Diabetes Mellitus Neurocognitive Function Monogenic Diabetes Syndromes Hypoglycemia Cystic Fibrosis–Related Diabetes Treatment Goals Posttransplantation Diabetes Mellitus Pharmacologic Therapy Treatment in Skilled Nursing Facilities S25 3. Comprehensive Medical Evaluation and and Nursing Homes Assessment of Comorbidities End-of-Life Care Patient-Centered Collaborative Care S105 12. Children and Adolescents Comprehensive Medical Evaluation Assessment of Comorbidities Type 1 Diabetes Type 2 Diabetes S33 4. Lifestyle Management Transition From Pediatric to Adult Care Diabetes Self-management Education and Support Nutrition Therapy S114 13. Management of Diabetes in Pregnancy Physical Activity Diabetes in Pregnancy Smoking Cessation: Tobacco and e-Cigarettes Preconception Counseling Psychosocial Issues Glycemic Targets in Pregnancy Management of Gestational Diabetes Mellitus S44 5. Prevention or Delay of Type 2 Diabetes Management of Preexisting Type 1 Diabetes Lifestyle Interventions and Type 2 Diabetes in Pregnancy Pharmacologic Interventions Postpartum Care Prevention of Cardiovascular Disease Pregnancy and Drug Considerations Diabetes Self-management Education and Support S120 14. Diabetes Care in the Hospital S48 6. Glycemic Targets Hospital Care Delivery Standards Assessment of Glycemic Control Glycemic Targets in Hospitalized Patients A1C Testing Bedside Blood Glucose Monitoring A1C Goals Antihyperglycemic Agents in Hospitalized Hypoglycemia Patients Intercurrent Illness Hypoglycemia S57 7. Obesity Management for the Treatment of Type 2 Medical Nutrition Therapy in the Hospital Diabetes Self-management in the Hospital Standards for Special Situations Assessment Transition From the Acute Care Setting Diet, Physical Activity, and Behavioral Therapy Preventing Admissions and Readmissions Pharmacotherapy Metabolic Surgery S128 15. Diabetes Advocacy S64 8. Pharmacologic Approaches to Glycemic Advocacy Position Statements Treatment S130 Professional Practice Committee Disclosures Pharmacologic Therapy for Type 1 Diabetes Pharmacologic Therapy for Type 2 Diabetes S132 Index This issue is freely accessible online at care.diabetesjournals.org. Keep up with the latest information for Diabetes Care and other ADA titles via Facebook (/ADAJournals) and Twitter (@ADA_Journals). Diabetes Care Volume 40, Supplement 1, January 2017 S1 INTRODUCTION Introduction Diabetes Care 2017;40(Suppl. 1):S1–S2 | DOI: 10.2337/dc17-S001 Diabetes is a complex, chronic illness re- ADA’s clinical practice recommendations Consensus Report quiring continuous medical care with are viewed as important resources for A consensus report contains a compre- multifactorial risk-reduction strategies health care professionals who care for hensive examination by an expert panel beyond glycemic
Load more

Recommended publications
  • Sorbonne Université/China Scholarship Council Program 2021
    Sorbonne Université/China Scholarship Council program 2021 Thesis proposal Title of the research project: Hnf1b regulation during kidney development and regeneration Joint supervision: no Joint PhD (cotutelle): no Thesis supervisor: … Muriel Umbhauer. Email address of the thesis supervisor: [email protected] Institution: …… Sorbonne Université …. Doctoral school (N°+name): ED …. …… ED 515 Complexité du Vivant Research laboratory: UMR7622 CNRS Laboratory of developmental biology Name of the laboratory director: … Sylvie Schneider-Maunoury Email address of the laboratory director: [email protected] Subject description (2 pages max): 1) Study context The POU homeodomain transcription factor hepatocyte nuclear factor 1β (Hnf1b) plays an essential role in vertebrate kidney development. Heterozygous mutations in human HNF1B cause the complex multisystem syndrome known as Renal Cysts And Diabetes (RCAD). The most prominent clinical features of this autosomal dominant disorder are non-diabetic renal disease resulting from abnormal renal development and diabetes mellitus (reviewed by Clissold RL et al., 2015). During early mouse kidney development, Hnf1b has been shown to be required for ureteric bud branching and initiation of nephrogenesis (Lokmane et al., 2010). Hnf1b conditional inactivation in murine nephron progenitors has revealed an additional role in segment fate Xenopus is a well established and attractive model to study kidney development (Krneta-Stankic V. et al, 2017). Renal function at larval stages relies on two pronephroi located on both sides of the body, each consisting on one giant nephron displaying the same structural and functional organisation than the mammalian nephron. Moreover, pronephric and metanephric differentiation and morphogenesis share most of the signalling cascades and gene regulatory networks.
    [Show full text]
  • Overlap of Vitamin a and Vitamin D Target Genes with CAKUT- Related Processes [Version 1; Peer Review: 1 Approved with Reservations]
    F1000Research 2021, 10:395 Last updated: 21 JUL 2021 BRIEF REPORT Overlap of vitamin A and vitamin D target genes with CAKUT- related processes [version 1; peer review: 1 approved with reservations] Ozan Ozisik1, Friederike Ehrhart 2,3, Chris T Evelo 2, Alberto Mantovani4, Anaı̈s Baudot 1,5 1Aix Marseille University, Inserm, MMG, Marseille, 13385, France 2Department of Bioinformatics - BiGCaT, Maastricht University, Maastricht, 6200 MD, The Netherlands 3Department of Bioinformatics, NUTRIM/MHeNs, Maastricht University, Maastricht, 6200 MD, The Netherlands 4Istituto Superiore di Sanità, Rome, 00161, Italy 5Barcelona Supercomputing Center (BSC), Barcelona, 08034, Spain v1 First published: 18 May 2021, 10:395 Open Peer Review https://doi.org/10.12688/f1000research.51018.1 Latest published: 18 May 2021, 10:395 https://doi.org/10.12688/f1000research.51018.1 Reviewer Status Invited Reviewers Abstract Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) are a 1 group of abnormalities affecting the kidneys and their outflow tracts, which include the ureters, the bladder, and the urethra. CAKUT version 1 patients display a large clinical variability as well as a complex 18 May 2021 report aetiology, as only 5% to 20% of the cases have a monogenic origin. It is thereby suspected that interactions of both genetic and 1. Elena Menegola, Università degli Studi di environmental factors contribute to the disease. Vitamins are among the environmental factors that are considered for CAKUT aetiology. In Milano, Milan, Italy this study, we collected vitamin A and vitamin D target genes and Any reports and responses or comments on the computed their overlap with CAKUT-related gene sets.
    [Show full text]
  • The Wittelsbach-Graff and Hope Diamonds: Not Cut from the Same Rough
    THE WITTELSBACH-GRAFF AND HOPE DIAMONDS: NOT CUT FROM THE SAME ROUGH Eloïse Gaillou, Wuyi Wang, Jeffrey E. Post, John M. King, James E. Butler, Alan T. Collins, and Thomas M. Moses Two historic blue diamonds, the Hope and the Wittelsbach-Graff, appeared together for the first time at the Smithsonian Institution in 2010. Both diamonds were apparently purchased in India in the 17th century and later belonged to European royalty. In addition to the parallels in their histo- ries, their comparable color and bright, long-lasting orange-red phosphorescence have led to speculation that these two diamonds might have come from the same piece of rough. Although the diamonds are similar spectroscopically, their dislocation patterns observed with the DiamondView differ in scale and texture, and they do not show the same internal strain features. The results indicate that the two diamonds did not originate from the same crystal, though they likely experienced similar geologic histories. he earliest records of the famous Hope and Adornment (Toison d’Or de la Parure de Couleur) in Wittelsbach-Graff diamonds (figure 1) show 1749, but was stolen in 1792 during the French T them in the possession of prominent Revolution. Twenty years later, a 45.52 ct blue dia- European royal families in the mid-17th century. mond appeared for sale in London and eventually They were undoubtedly mined in India, the world’s became part of the collection of Henry Philip Hope. only commercial source of diamonds at that time. Recent computer modeling studies have established The original ancestor of the Hope diamond was that the Hope diamond was cut from the French an approximately 115 ct stone (the Tavernier Blue) Blue, presumably to disguise its identity after the that Jean-Baptiste Tavernier sold to Louis XIV of theft (Attaway, 2005; Farges et al., 2009; Sucher et France in 1668.
    [Show full text]
  • The Tubesat Launch Vehicle
    TubeSat and NEPTUNE 30 Orbital Rocket Programs Personal Satellites Are GO! Interorbital Systems www.interorbital.com About Interorbital Corporation Founded in 1996 by Randa and Roderick Milliron, incorporated in 2001 Located at the Mojave Spaceport in Mojave, California 98.5% owned by R. and R. Milliron 1.5% owned by Eric Gullichsen Initial Starting Technology Pressure-fed liquid rocket engines Initial Mission Low-cost orbital and interplanetary launch vehicle development Facilities 6,000 square-foot research and development facility Two rocket engine test sites at the Mojave Spaceport Expert engineering and manufacturing team Interorbital Systems www.interorbital.com Core Technical Team Roderick Milliron: Chief Designer Lutz Kayser: Primary Technical Consultant Eric Gullichsen: Guidance and Control Gerard Auvray: Telecommunications Engineer Donald P. Bennett: Mechanical Engineer David Silsbee: Electronics Engineer Joel Kegel: Manufacturing/Engineering Tech Jacqueline Wein: Manufacturing/Engineering Tech Reinhold Ziegler: Space-Based Power Systems E. Mark Shusterman,M.D. Medical Life Support Randa Milliron: High-Temperature Composites Interorbital Systems www.interorbital.com Key Hardware Built In-House Propellant Tanks: Combining state-of-the-art composite technology with off-the-shelf aluminum liners Advanced Guidance Hardware and Software Ablative Rocket Engines and Components GPRE 0.5KNFA Rocket Engine Test Manned Space Flight Training Systems Rocket Injectors, Valves Systems, and Other Metal components Interorbital Systems www.interorbital.com Project History Pressure-Fed Rocket Engines GPRE 2.5KLMA Liquid Oxygen/Methanol Engine: Thrust = 2,500 lbs. GPRE 0.5KNFA WFNA/Furfuryl Alcohol (hypergolic): Thrust = 500 lbs. GPRE 0.5KNHXA WFNA/Turpentine (hypergolic): Thrust = 500 lbs. GPRE 3.0KNFA WFNA/Furfuryl Alcohol (hypergolic): Thrust = 3,000 lbs.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Supplemental Materials ZNF281 Enhances Cardiac Reprogramming
    Supplemental Materials ZNF281 enhances cardiac reprogramming by modulating cardiac and inflammatory gene expression Huanyu Zhou, Maria Gabriela Morales, Hisayuki Hashimoto, Matthew E. Dickson, Kunhua Song, Wenduo Ye, Min S. Kim, Hanspeter Niederstrasser, Zhaoning Wang, Beibei Chen, Bruce A. Posner, Rhonda Bassel-Duby and Eric N. Olson Supplemental Table 1; related to Figure 1. Supplemental Table 2; related to Figure 1. Supplemental Table 3; related to the “quantitative mRNA measurement” in Materials and Methods section. Supplemental Table 4; related to the “ChIP-seq, gene ontology and pathway analysis” and “RNA-seq” and gene ontology analysis” in Materials and Methods section. Supplemental Figure S1; related to Figure 1. Supplemental Figure S2; related to Figure 2. Supplemental Figure S3; related to Figure 3. Supplemental Figure S4; related to Figure 4. Supplemental Figure S5; related to Figure 6. Supplemental Table S1. Genes included in human retroviral ORF cDNA library. Gene Gene Gene Gene Gene Gene Gene Gene Symbol Symbol Symbol Symbol Symbol Symbol Symbol Symbol AATF BMP8A CEBPE CTNNB1 ESR2 GDF3 HOXA5 IL17D ADIPOQ BRPF1 CEBPG CUX1 ESRRA GDF6 HOXA6 IL17F ADNP BRPF3 CERS1 CX3CL1 ETS1 GIN1 HOXA7 IL18 AEBP1 BUD31 CERS2 CXCL10 ETS2 GLIS3 HOXB1 IL19 AFF4 C17ORF77 CERS4 CXCL11 ETV3 GMEB1 HOXB13 IL1A AHR C1QTNF4 CFL2 CXCL12 ETV7 GPBP1 HOXB5 IL1B AIMP1 C21ORF66 CHIA CXCL13 FAM3B GPER HOXB6 IL1F3 ALS2CR8 CBFA2T2 CIR1 CXCL14 FAM3D GPI HOXB7 IL1F5 ALX1 CBFA2T3 CITED1 CXCL16 FASLG GREM1 HOXB9 IL1F6 ARGFX CBFB CITED2 CXCL3 FBLN1 GREM2 HOXC4 IL1F7
    [Show full text]
  • UNIVERSITY of CALIFORNIA, IRVINE Combinatorial Regulation By
    UNIVERSITY OF CALIFORNIA, IRVINE Combinatorial regulation by maternal transcription factors during activation of the endoderm gene regulatory network DISSERTATION submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in Biological Sciences by Kitt D. Paraiso Dissertation Committee: Professor Ken W.Y. Cho, Chair Associate Professor Olivier Cinquin Professor Thomas Schilling 2018 Chapter 4 © 2017 Elsevier Ltd. © 2018 Kitt D. Paraiso DEDICATION To the incredibly intelligent and talented people, who in one way or another, helped complete this thesis. ii TABLE OF CONTENTS Page LIST OF FIGURES vii LIST OF TABLES ix LIST OF ABBREVIATIONS X ACKNOWLEDGEMENTS xi CURRICULUM VITAE xii ABSTRACT OF THE DISSERTATION xiv CHAPTER 1: Maternal transcription factors during early endoderm formation in 1 Xenopus Transcription factors co-regulate in a cell type-specific manner 2 Otx1 is expressed in a variety of cell lineages 4 Maternal otx1 in the endodermal conteXt 5 Establishment of enhancers by maternal transcription factors 9 Uncovering the endodermal gene regulatory network 12 Zygotic genome activation and temporal control of gene eXpression 14 The role of maternal transcription factors in early development 18 References 19 CHAPTER 2: Assembly of maternal transcription factors initiates the emergence 26 of tissue-specific zygotic cis-regulatory regions Introduction 28 Identification of maternal vegetally-localized transcription factors 31 Vegt and OtX1 combinatorially regulate the endodermal 33 transcriptome iii
    [Show full text]
  • Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma
    cancers Review Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma Ken Yamaguchi 1,*, Sachiko Kitamura 1, Yoko Furutake 1 , Ryusuke Murakami 1,2 , Koji Yamanoi 1, Mana Taki 1, Masayo Ukita 1, Junzo Hamanishi 1 and Masaki Mandai 1 1 Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan; [email protected] (S.K.); [email protected] (Y.F.); [email protected] (R.M.); [email protected] (K.Y.); [email protected] (M.T.); [email protected] (M.U.); [email protected] (J.H.); [email protected] (M.M.) 2 Department of Gynecology, Shiga General Hospital, Moriyama, Shiga 524-8524, Japan * Correspondence: [email protected]; Tel.: +81-75-751-3269 Simple Summary: Ovarian clear cell carcinoma (CCC) exhibits unique characteristics, including slow growth, glycogen accumulation in the cytoplasm, and poor prognosis for stress resistance. Several molecular targeting agents have failed to treat ovarian CCC. Recent reports have identified metabolic alterations through HNF1B, which is highly expressed in ovarian CCC. The Warburg effect, GSH synthesis, and mitochondrial regulation occur in CCC. The metabolic behaviors of ovarian CCC resemble the evolution of life to survive in stressful environments. Understanding the fundamental biology of ovarian CCC might help in the development of novel therapeutic strategies. Citation: Yamaguchi, K.; Kitamura, Abstract: Clear cell carcinoma (CCC) of the ovary exhibits a unique morphology and clinically S.; Furutake, Y.; Murakami, R.; malignant behavior.
    [Show full text]
  • Trade Studies Towards an Australian Indigenous Space Launch System
    TRADE STUDIES TOWARDS AN AUSTRALIAN INDIGENOUS SPACE LAUNCH SYSTEM A thesis submitted for the degree of Master of Engineering by Gordon P. Briggs B.Sc. (Hons), M.Sc. (Astron) School of Engineering and Information Technology, University College, University of New South Wales, Australian Defence Force Academy January 2010 Abstract During the project Apollo moon landings of the mid 1970s the United States of America was the pre-eminent space faring nation followed closely by only the USSR. Since that time many other nations have realised the potential of spaceflight not only for immediate financial gain in areas such as communications and earth observation but also in the strategic areas of scientific discovery, industrial development and national prestige. Australia on the other hand has resolutely refused to participate by instituting its own space program. Successive Australian governments have preferred to obtain any required space hardware or services by purchasing off-the-shelf from foreign suppliers. This policy or attitude is a matter of frustration to those sections of the Australian technical community who believe that the nation should be participating in space technology. In particular the provision of an indigenous launch vehicle that would guarantee the nation independent access to the space frontier. It would therefore appear that any launch vehicle development in Australia will be left to non- government organisations to at least define the requirements for such a vehicle and to initiate development of long-lead items for such a project. It is therefore the aim of this thesis to attempt to define some of the requirements for a nascent Australian indigenous launch vehicle system.
    [Show full text]
  • NICU Gene List Generator.Xlsx
    Neonatal Crisis Sequencing Panel Gene List Genes: A2ML1 - B3GLCT A2ML1 ADAMTS9 ALG1 ARHGEF15 AAAS ADAMTSL2 ALG11 ARHGEF9 AARS1 ADAR ALG12 ARID1A AARS2 ADARB1 ALG13 ARID1B ABAT ADCY6 ALG14 ARID2 ABCA12 ADD3 ALG2 ARL13B ABCA3 ADGRG1 ALG3 ARL6 ABCA4 ADGRV1 ALG6 ARMC9 ABCB11 ADK ALG8 ARPC1B ABCB4 ADNP ALG9 ARSA ABCC6 ADPRS ALK ARSL ABCC8 ADSL ALMS1 ARX ABCC9 AEBP1 ALOX12B ASAH1 ABCD1 AFF3 ALOXE3 ASCC1 ABCD3 AFF4 ALPK3 ASH1L ABCD4 AFG3L2 ALPL ASL ABHD5 AGA ALS2 ASNS ACAD8 AGK ALX3 ASPA ACAD9 AGL ALX4 ASPM ACADM AGPS AMELX ASS1 ACADS AGRN AMER1 ASXL1 ACADSB AGT AMH ASXL3 ACADVL AGTPBP1 AMHR2 ATAD1 ACAN AGTR1 AMN ATL1 ACAT1 AGXT AMPD2 ATM ACE AHCY AMT ATP1A1 ACO2 AHDC1 ANK1 ATP1A2 ACOX1 AHI1 ANK2 ATP1A3 ACP5 AIFM1 ANKH ATP2A1 ACSF3 AIMP1 ANKLE2 ATP5F1A ACTA1 AIMP2 ANKRD11 ATP5F1D ACTA2 AIRE ANKRD26 ATP5F1E ACTB AKAP9 ANTXR2 ATP6V0A2 ACTC1 AKR1D1 AP1S2 ATP6V1B1 ACTG1 AKT2 AP2S1 ATP7A ACTG2 AKT3 AP3B1 ATP8A2 ACTL6B ALAS2 AP3B2 ATP8B1 ACTN1 ALB AP4B1 ATPAF2 ACTN2 ALDH18A1 AP4M1 ATR ACTN4 ALDH1A3 AP4S1 ATRX ACVR1 ALDH3A2 APC AUH ACVRL1 ALDH4A1 APTX AVPR2 ACY1 ALDH5A1 AR B3GALNT2 ADA ALDH6A1 ARFGEF2 B3GALT6 ADAMTS13 ALDH7A1 ARG1 B3GAT3 ADAMTS2 ALDOB ARHGAP31 B3GLCT Updated: 03/15/2021; v.3.6 1 Neonatal Crisis Sequencing Panel Gene List Genes: B4GALT1 - COL11A2 B4GALT1 C1QBP CD3G CHKB B4GALT7 C3 CD40LG CHMP1A B4GAT1 CA2 CD59 CHRNA1 B9D1 CA5A CD70 CHRNB1 B9D2 CACNA1A CD96 CHRND BAAT CACNA1C CDAN1 CHRNE BBIP1 CACNA1D CDC42 CHRNG BBS1 CACNA1E CDH1 CHST14 BBS10 CACNA1F CDH2 CHST3 BBS12 CACNA1G CDK10 CHUK BBS2 CACNA2D2 CDK13 CILK1 BBS4 CACNB2 CDK5RAP2
    [Show full text]
  • Study of a 100Kwe Space Reactor for Exploration Missions
    Preliminary study of a 100 kWe space reactor concept for exploration missions Elisa CLIQUET, Jean-Marc RUAULT 1), Jean-Pierre ROUX, Laurent LAMOINE, Thomas RAMEE 2), Christine POINOT-SALANON, Alexey LOKHOV, Serge PASCAL 3) 1) CNES Launchers Directorate,Evry, France 2) AREVA TA, Aix en Provence, France 3) CEA DEN/DM2S, F-91191 Gif-sur-Yvette, France NETS 2011 Overview ■ General context of the study ■ Requirements ■ Methodology of the study ■ Technologies selected for final trade-off ■ Reactor trade-off ■ Conversion trade-off ■ Critical technologies and development philosophy ■ Conclusion and perspectives CNES Directorate of Launchers Space transportation division of the French space agency ■ Responsible for the development of DIAMANT, ARIANE 1 to 4, ARIANE 5, launchers ■ System Architect for the Soyuz at CSG program ■ Development of VEGA launcher first stage (P80) ■ Future launchers preparation activities Multilateral and ESA budgets • To adapt the current launchers to the needs for 2015-2020 • To prepare launcher evolutions for 2025 - 2030, if needed • To prepare the new generation of expandable launchers (2025-2030) • To prepare the long future after 2030 with possible advanced launch vehicles ■ Future space transportation prospective activities, such as Exploration needs (including in particular OTV missions) Advanced propulsion technologies investigation General context ■ Background Last French studies on space reactors : • ERATO (NEP) in the 80’s, • MAPS (NTP) in the 90’s • OPUS (NEP) 2002-2004 ■ Since then Nuclear safe orbit
    [Show full text]
  • 1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
    xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A
    [Show full text]